Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma
Published 4 months ago
Description
In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.